MX2022009784A - Terapia anti-bcma en trastornos autoinmunes. - Google Patents

Terapia anti-bcma en trastornos autoinmunes.

Info

Publication number
MX2022009784A
MX2022009784A MX2022009784A MX2022009784A MX2022009784A MX 2022009784 A MX2022009784 A MX 2022009784A MX 2022009784 A MX2022009784 A MX 2022009784A MX 2022009784 A MX2022009784 A MX 2022009784A MX 2022009784 A MX2022009784 A MX 2022009784A
Authority
MX
Mexico
Prior art keywords
autoimmune disorders
bcma therapy
bcma
therapy
anca
Prior art date
Application number
MX2022009784A
Other languages
English (en)
Inventor
Robert Plenge
Kofi Mensah
Sophie Roy
Dennis Zaller
Jennifer Dovey
Steven Saenz
Jill Henault
Camille Doykan
Jenna Calvino
Xi Jin
Joseph Paquette
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2022009784A publication Critical patent/MX2022009784A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere al tratamiento o manejo de trastornos autoinmunes, tales como trastornos autoinmunes causado por células de linaje B autorreactivas, por ejemplo, vasculitis asociada al anticuerpo anti-citoplasma de neutrófilos (ANCA) (AAV).
MX2022009784A 2020-02-12 2021-02-11 Terapia anti-bcma en trastornos autoinmunes. MX2022009784A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062975663P 2020-02-12 2020-02-12
PCT/US2021/017665 WO2021163329A1 (en) 2020-02-12 2021-02-11 Anti-bcma therapy in autoimmune disorders

Publications (1)

Publication Number Publication Date
MX2022009784A true MX2022009784A (es) 2022-09-09

Family

ID=77291870

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022009784A MX2022009784A (es) 2020-02-12 2021-02-11 Terapia anti-bcma en trastornos autoinmunes.

Country Status (11)

Country Link
US (1) US20240052064A1 (es)
EP (1) EP4103224A4 (es)
JP (1) JP2023514224A (es)
KR (1) KR20220141306A (es)
CN (1) CN115551539A (es)
AU (1) AU2021221123A1 (es)
BR (1) BR112022014646A2 (es)
CA (1) CA3169696A1 (es)
IL (1) IL295471A (es)
MX (1) MX2022009784A (es)
WO (1) WO2021163329A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6708635B2 (ja) 2014-10-09 2020-06-10 エンクマフ エスアーエールエル ＣＤ３εおよびＲＯＲ１に対する二特異性抗体
WO2023044633A1 (zh) * 2021-09-22 2023-03-30 南京驯鹿医疗技术有限公司 Bcma car-t在制备用于治疗自身免疫病的药物中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018001955B1 (pt) * 2015-08-03 2021-05-11 Engmab Sárl anticorpo monoclonal que se liga às células b humanas (bcma), composição farmacêutica e seu uso
BR112020008323A2 (pt) * 2017-11-01 2020-11-03 Juno Therapeutics Inc anticorpos e receptores de antígenos quiméricos específicos para antígeno de maturação de células b

Also Published As

Publication number Publication date
WO2021163329A1 (en) 2021-08-19
US20240052064A1 (en) 2024-02-15
BR112022014646A2 (pt) 2022-09-13
IL295471A (en) 2022-10-01
EP4103224A4 (en) 2023-08-16
EP4103224A1 (en) 2022-12-21
AU2021221123A1 (en) 2022-10-06
CN115551539A (zh) 2022-12-30
CA3169696A1 (en) 2021-08-19
KR20220141306A (ko) 2022-10-19
JP2023514224A (ja) 2023-04-05

Similar Documents

Publication Publication Date Title
MX2022009784A (es) Terapia anti-bcma en trastornos autoinmunes.
MX2022009187A (es) Antifolatos poliglutamados alfa y gamma-d y sus usos.
MX2019013172A (es) Composiciones y metodos para tratar la enfermedad de huntington.
MX2021000708A (es) Anticuerpos de cadena pesada que se unen al cd19.
WO2018134787A3 (en) Compositions and methods for the depletion of cd137+ cells
MX2018014152A (es) Composiciones y métodos para tratar la enfermedad de huntington.
WO2019014328A3 (en) AGONISTIC ANTIBODIES THAT BIND HUMAN CD137 AND USES THEREOF
EA201100663A1 (ru) Соединения, которые увеличивают количество гематопоэтических стволовых клеток
PH12021550690A1 (en) Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies
SV2011003807A (es) Composiciones y metodos de uso para anticuerpos terapeuticos
MX2020012061A (es) Composiciones que comprenden cepas bacterianas.
MX2021015337A (es) Anticuerpos multiespecificos de cadena pesada que se unen a cd22 y cd3.
MX2020011254A (es) Celulas t car anti-bcma para agotamiento de celulas de plasma.
CR20200450A (es) Anticuerpos anti-trem-l y usos de los mismos
MX2022005692A (es) Metodos y composiciones para el tratamiento de un trastorno asociado con angiotensinogeno (agt).
MX2021008796A (es) Anticuerpos contra subunidad alfa il-7r y usos de estos.
MX2023011725A (es) Anticuerpos anti-cd19 y estructuras car-t.
MX2023009882A (es) Anticuerpos anti-muc1-c y estructuras car-t.
MX2023009100A (es) Agentes aglutinantes y métodos para usar los mismos.
MX2021005751A (es) Anticuerpos contra mucina 16 y métodos de uso de los mismos.
MX2023005699A (es) Anticuerpos biespecificos para el uso en el tratamiento de inflamasomopatia nlrc4-gof.
BR112021018684A2 (pt) Métodos para aumentar a eficiência de esgotamento de células tcr¿¿+
JOP20190275A1 (ar) طرق وتركيبات لعلاج اضطراب إسهال خِلقي
WO2022023292A3 (en) Corona virus spike protein-targeting antibodies and use thereof
MX2021015045A (es) Construcciones de unión biespecíficas.